Charlie's Holdings (OTCQB:CHUC) Announces Opening of US Manufacturing Facility and First Shipments to Texas Customers

Author's Summary

Charlie's Holdings has launched its first US manufacturing facility in California, enabling compliant Pachamama product shipments to 300 Texas retailers, with potential to double 2026 sales projections amid new regulations. (152 characters)

Key Announcement

Charlie's Holdings, Inc. (OTCQB:CHUC), a leader in premium vapor products, opened its inaugural US manufacturing facility in Huntington Beach, California. This site uses advanced machinery and skilled staff to produce its own brands, including the Pachamama 25K Disposables filled domestically. Shipments began this week to 300 retail locations across Texas.

Compliance and Market Edge

The facility ensures Pachamama products fully comply with Texas's strict domestic manufacturing rules and similar standards in other major states. Unlike rivals relying on Chinese imports or shared foreign production, Charlie's now offers US-filled vapor products. This positions Pachamama—operational for over a decade—as a compliant pioneer appealing to buyers preferring "Made in America" items.

Leadership Statements

Henry Sicignano III, President, noted: > Initially, we anticipated our US filling facility would alleviate delays in shipping from the Far East and reduce tariff expenses, but the new manufacturing regulations in Texas have also opened up a substantial sales opportunity for us. He added plans to dedicate 100% of current capacity to Texas, potentially doubling 2026 sales if expansion succeeds.

Ryan Stump, co-founder and COO, stated: > To knowledge, Pachamama is the vapor product brand that has been operational for over a decade and now fully complies with Texas's domestic manufacturing standards. Our award-winning flavors, strong brand recognition, and commitment to regulatory compliance provide us with significant competitive advantages that truly distinguish us.

Forward-Looking Risks

Statements involve risks like regulatory hurdles, FDA approvals for PMTA submissions, sales growth challenges, and competition, as detailed in recent SEC filings. Actual results may differ significantly.

more

Yahoo Finance Yahoo Finance — 2025-12-01

More News